- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- April 2025
- 200 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- February 2025
- 200 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- July 2025
- 278 Pages
Global
From €5184EUR$5,850USD£4,465GBP
- Report
- June 2025
- 400 Pages
Global
From €4386EUR$4,949USD£3,777GBP
- Report
- May 2024
- 138 Pages
Global
From €5759EUR$6,499USD£4,960GBP
- Report
- May 2024
- 137 Pages
Global
From €5759EUR$6,499USD£4,960GBP
- Report
- May 2024
- 128 Pages
Global
From €5759EUR$6,499USD£4,960GBP
Xeomin is a prescription medication used to treat musculoskeletal disorders, such as cervical dystonia, blepharospasm, and strabismus. It is a neuromodulator, meaning it works by blocking the release of certain chemicals in the brain that cause muscle contractions. Xeomin is administered through injections directly into the affected muscle. It is a relatively new drug, having been approved by the FDA in 2011.
Xeomin is a popular choice for treating musculoskeletal disorders due to its efficacy and safety profile. It is well-tolerated and has few side effects. It is also easy to administer and does not require refrigeration.
The Xeomin market is highly competitive, with several companies offering the drug. These include Merz Pharmaceuticals, Allergan, and Ipsen Biopharmaceuticals. Each company offers its own formulation of Xeomin, with varying concentrations and dosing schedules. Show Less Read more